Categoría Uncategorized

Sub-Tenon injection of mitomycin C may have advantages over sponge application

Sub-Tenon injection of mitomycin C may be an alternative to conventional application of MMC with sponges, according to a study.
The use of antimetabolites to prevent excessive postoperative scarring and reduce the risk for failure has become standard in glaucoma surgery. Since its first application in 1992, MMC has significantly improved the success rate of trabeculectomy. However, MMC has several potential toxicity-related side effects. Different concentrations and exposure times have therefore been tested to find the right balance between safety and efficacy.
In a prospective, randomized,

Celebrate orthopedic surgeons on National Doctors’ Day

National Doctors’ Day marks the anniversary of the first use of general anesthesia in surgery by Crawford W. Long, MD, on March 30, 1842. To celebrate, Healio Orthopedics revisits stories that reflect on the impact of orthopedic surgeons.
Amid the COVID-19 pandemic, John D. Kelly IV, MD, pauses and reflects on what calls many orthopedic physicians to a medical vocation. Directing attention and energy to serve patients can help physicians stay present, find purpose and take responsibility, Kelly said. Read more.
Anthony A. Romeo, MD, comments on how orthopedic physicians can optimize

VIDEO: More resources needed to strengthen primary care, improve health equity

In this video, Robert L. Phillips Jr., MD, MSPH, the director of the Center for Professionalism and Value in Health Care at the American Board of Family Medicine, discusses ways to strengthen primary care in the United States.
Phillips references an editorial he wrote in response to three papers published in Annals of Family Medicine that illustrate how “starved” primary care is for resources.
“We spend less than 1% of all federal research dollars in health care on primary care, yet primary care provides more than a third of all health care visits and more than half of all

Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint

A randomized phase 3 trial designed to assess the addition of tiragolumab to atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer failed to meet its co-primary endpoint of PFS.
Tiragolumab (Genentech) is a novel immune checkpoint inhibitor with an intact Fc region. The agent selectively binds to TIGIT, a novel inhibitory immune checkpoint that suppresses the immune response to cancer, according to a Genentech-issued press release.
Atezolizumab (Tecentriq, Genentech) is an anti-PD-L1 monoclonal antibody.
The global SKYSCRAPER-02 trial included 490

Celebrate National Doctors’ Day with advice from top allergy, asthma specialists

As Healio celebrates National Doctors' Day today, we recognize dedicated physicians we spoke with over the past year about how they are working both in the clinic and beyond to improve allergy, asthma and immunology care.
These exclusive Q&A interviews explore a range of topics, from how COVID-19 and climate change have impacted treatment to cutting-edge immunotherapies and biologics as well as the social determinants of health.
Amanda Cox, MD, FAAAAI, of the Icahn School of Medicine at Mount Sinai, reviews the guidance and research behind the early introduction of allergens in addition to

CRC patients with unresectable liver metastases may benefit from living-donor LT

Living-donor liver transplantation may be a viable option for patients with unresectable, liver-confined colorectal cancer liver metastases, according to a study published in JAMA Surgery.
“This study proves for the first time in North America the feasibility and efficacy of living-donor liver transplant in patients with colorectal liver metastases,” senior study author Gonzalo Sapisochin, MD, PhD, MSc, a transplant surgeon at Ajmera Transplant Center and associate professor of surgery at the University of Toronto, told Healio. “To date, all the information that we had was on